Related Experiment Videos
Regulation of Potassium Homeostasis in CKD
1Section on General Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC, and the Division of Nephrology, University of Virginia School of Medicine, Charlottesville, VA.
Insights
Potassium imbalances, or dyskalemias, significantly increase mortality risk in chronic kidney disease (CKD) patients. Understanding CKD-specific causes and management of hyperkalemia and hypokalemia is crucial for better patient outcomes.
Area of Science:
- Nephrology
- Endocrinology
- Internal Medicine
Background:
- Potassium homeostasis disturbances (hyperkalemia, hypokalemia) have serious consequences.
- Recent focus on chronic hypokalemia's impact and a U-shaped mortality curve in serum potassium levels.
- CKD uniquely affects dyskalemia pathophysiology and outcomes.
Purpose of the Study:
- To review the causes and pathophysiology of dyskalemias in CKD.
- To highlight the high mortality associated with both low and high potassium levels in CKD.
- To examine recent advances in potassium sensing and management strategies.
Main Methods:
- Review of recent studies on serum potassium levels and mortality.
- Detailed examination of renal potassium sensing mechanisms (DCT1, DCT2, ROMK).
- Analysis of drug-induced dyskalemias (calcineurin inhibitors, ACE inhibitors, ARBs) and novel therapeutic agents.
Main Results:
- A U-shaped relationship exists between serum potassium and mortality in CKD.
- Renal potassium sensing mechanisms can be disrupted by medications or inherited conditions.
- ACE inhibitors and ARBs commonly cause hyperkalemia, necessitating management strategies.
Conclusions:
- Both hyperkalemia and hypokalemia pose significant mortality risks in CKD patients.
- Understanding and managing potassium balance is critical throughout CKD progression.
- Dietary management, particularly potassium intake from fresh produce, needs greater emphasis in early CKD.
Abstract:
Disturbances of potassium homeostasis can cause either hyperkalemia or hypokalemia and result in serious consequences. Although the consequences of acute and chronic hyperkalemia and treatment of these conditions in CKD have been widely appreciated by nephrologists, more recent information has focused attention on the consequences of chronic hypokalemia. Several recent studies have documented a "U-shaped" relationship between the serum [K+] and higher mortality in several clinical studies. The causes of dyskalemias are placed into the unique perspective of patients with CKD and its evolution with progression of CKD to later stages and focuses on the pathophysiology of these disorders. Emphasis is placed on the high mortality associated with both low and high levels of potassium that are unique to patients with CKD. Recent information regarding sensors of changes in the serum [K+] that evoke changes in NaCl transport in the DCT1 and subsequent efferent responses by aldosterone-responsive cells in the DCT2 and cortical collecting duct to adjust K+ secretion by the renal outer medullary potassium channel is reviewed in detail. These sensing mechanisms can be interrupted by drugs, such as the calcineurin inhibitors to cause both hypertension and hyperkalemia in kidney transplant patients, or can be inherited as familial hypertensive hyperkalemia. The role and pathogenesis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in causing hyperkalemia is a common stop point for cessation of these important drugs, but, and newer agents to lower the serum [K+] that might allow continuation of angiotensin-converting enzyme or angiotensin receptor blocker therapy are examined. Finally, the importance of emphasis on potassium-containing foods, such as fresh produce and fruit in the diets of patients with early-stage CKD, is examined as an under-appreciated area requiring more emphasis by nephrologists caring for these patients and may be unique to food-challenged patients with CKD.